The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A.
Legler K, et al. Among authors: trauzold a.
Cell Death Dis. 2018 May 1;9(5):445. doi: 10.1038/s41419-018-0478-0.
Cell Death Dis. 2018.
PMID: 29670075
Free PMC article.